GlassScriptPhysician profile
Julie Weibert
NPI 1710036702
$2,491.86
in general payments reported to CMS, 2019-2025
12 companies · $697 in 2025
The $697 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $128 · 2021: $129 · 2022: $263 · 2023: $467 · 2024: $318 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $724.61 | 2019-2025 | Dailies Total1, Precision7, Precision 1 |
| Coopervision INC. | $461.86 | 2019-2024 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $305.45 | 2022-2025 | Infuse, Infuse Multifocal |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $276.93 | 2019-2021 | |
| Dompe US, INC. | $246.91 | 2023-2025 | Oxervate |
| Glaukos Corporation | $131.95 | 2019-2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $117.44 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $112.28 | 2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $39.11 | 2019-2025 | |
| Rxsight INC | $38.46 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Light Adjustable Lens (Rxlal) |
| Novartis Pharmaceuticals Corporation | $21.74 | 2019 | |
| Allergan, INC. | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Weibert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.